Optimer Rides High After OPT-80 C. Difficile Trial Success
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Optimer Pharmaceuticals saw its share price double from around $4 to $8 after it released data from a Phase III trial showing its orally dosed first-in-class macrocyclic antibiotic was at least as good as Vancocin (ViroPharma's oral vancomycin) - and possibly better - at treating the hospital scourge Clostridium difficile.
You may also be interested in...
Genzyme’s Tolevamer Misses Endpoint In First Of Two Phase III Studies
“We don’t believe tolevamer will be commercialized in the near future,” Genzyme tells “The Pink Sheet” DAILY.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.